COVID-19 developers have been announcing that they will discontinue their clinical trials one after another. In just 10 days, Celltrion, Chong Kun Dang, and CrystalGenomics publicly announced that they will discontinue their COVID-19 clinical trials. When counting from January, the number increases to 5 with Genexine and HK Inno.N.

The news of the discontinuation was received with the response that it was as expected. However, there is no reason for the companies to be criticized for discontinuing their clinical trials. Strictly speaking, only 10% of the drugs succeed in receiving final approval for their treatment or vaccine after initiating clinical trials.

Rather, the companies can b